| Literature DB >> 31037772 |
Meizhu Wang1,2, Yu Cao3, Maoning Xia4, Abdullah M S Al-Hatmi2,5,6, Weizheng Ou7, Yanyan Wang8, Andriy A Sibirny9,10, Liang Zhao1, Chenggang Zou11, Wanqing Liao12, Fengyan Bai13, Xie Zhi14, Sybren de Hoog2,6, Yingqian Kang1,3.
Abstract
A set of 185 strains of Candida albicans from patients with vulvovaginal candidiasis (VVC) and from non-VVC clinical sources in southwest China was analysed. Strains were subjected to genotyping using CAI microsatellite typing and amplification of an intron-containing region of the 25S rRNA gene. Microsatellite genotypes of strains from non-VVC sources showed high polymorphism, whereas those of VVC were dominated by few, closely similar genotypes. However, among non-VVC strains, two genotypes were particularly prevalent in patients with lung cancer. 25S rDNA genotype A was dominant in VVC sources (86.7%), whereas genotypes A, B, and C were rather evenly distributed among non-VVC sources; known genotypes D and E were not found. In an experimental mouse model, isolates from lung cancer and AIDS patients proved to have higher virulence than VVC strains. Among 156 mice infected with C. albicans, 19 developed non-invasive urothelial carcinoma. No correlation could be established between parameters of virulence, source of infection, and incidence of carcinoma. C. albicans strains from VVC were less susceptible to itraconazole than the strains from non-VVC sources, whereas there was small difference in antifungal susceptibility between different 25S rDNA genotypes of C. albicans tested against amphotericin B, itraconazole, fluconazole, and flucytosine.Entities:
Keywords: 25S rDNA genotype; CAI microsatellite genotype; Candida albicans; antifungal susceptibility; urothelial carcinoma
Mesh:
Substances:
Year: 2019 PMID: 31037772 PMCID: PMC6618086 DOI: 10.1002/yea.3397
Source DB: PubMed Journal: Yeast ISSN: 0749-503X Impact factor: 3.239
Occurrence of carcinoma in mice infected with
| Group | No. | CAI genotype | Source | 30–60 days | 61–90 days | 91–120 days | 121–168 days | Number of carcinomas | Percentage incidence |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GYF006 | 30–45 | VVC | L(1) | 1 | 8.3 | |||
| 2 | GYZ249 | 21–21 | Lung cancer | L(1) | L(1)/H(2) | 4 | 33.3 | ||
| 3 | ATCC10231 | Untested | Bronchopneumonia | H(1) | 1 | 8.3 | |||
| 4 | GYWu27 | 21–21 | HIV/AIDS | 0 | 0.0 | ||||
| 5 | GYWu45 | 21–21 | HIV/AIDS | L(1) | H(1) | 2 | 16.7 | ||
| 6 | GYF76 | 32–46 | VVC | H(1) | 1 | 8.3 | |||
| 7 | GYWu20 | 21–33 | HIV/AIDS | H(1) | 1 | 8.3 | |||
| 8 | GYF091 | 30–46 | VVC | L(1)/H(1) | 2 | 16.7 | |||
| 9 | GYZ210 | 21–33 | Lung cancer | H(1) | H(1) | 2 | 16.7 | ||
| 10 | GYZ072 | 21–33 | Lung cancer | H(1) | 1 | 8.3 | |||
| 11 | BK60 | Untested | Healthy host | H(1) | 1 | 8.3 | |||
| 12 | S165 | Untested | Healthy host | H(1) | H(1) | 2 | 16.7 | ||
| 13 | 1107 | Untested | Healthy host | H(1) | 1 | 8.3 | |||
| 14 | Saline | ‐ | ‐ | 0 | 0.0 |
Note. H, non‐invasive urothelial carcinoma, high grade; L, non‐invasive urothelial carcinoma, low grade.
Abbreviation: VVC, vulvovaginal candidiasis.
Figure 1Construction of an unweighted pair group method with arithmetic means distance tree of CAI gene with 185 strains isolated from vulvovaginal candidiasis (VVC) and non‐VVC. The blue rectangle‐marked strains are isolated from VVC; and red rectangle marked strains are isolated from non‐VVC. COPD: chronic obstructive pulmonary disease; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; AIDS: acquired immunodeficiency syndrome; RA: rheumatoid arthritis; URI: upper respiratory tract infection; TB: tuberculosis; AML‐M2: acute myeloblastic leukaemia with differentiation; CAP: community‐acquired pneumonia; CHD: congenital heart defect; UGIB: upper gastrointestinal bleeding; T2DM: diabetes mellitus type 2 [Colour figure can be viewed at wileyonlinelibrary.com]
Results of four antifungal drugs against from VVC and non‐VVC
| Antifungal | MIC (μg/ml) | VVC | Non‐VVC |
|---|---|---|---|
| Amphotericin B | MIC range | 0.125–1 | 0.25–1 |
| GM MIC | 0.70 | 0.71 | |
| MIC50 | 1 | 1 | |
| MIC90 | 1 | 1 | |
| 5‐Fluorocytosine | MIC range | 0.25–64 | <0.125 to >64 |
| GM MIC | 1.77 | 0.18 | |
| MIC50 | 2 | 0.125 | |
| MIC90 | 4 | 0.25 | |
| Fluconazole | MIC range | 0.06–64 | 0.125 to >64 |
| GM MIC | 1.71 | 0.91 | |
| MIC50 | 2 | 0.5 | |
| MIC90 | 8 | 4 | |
| Itraconazole | MIC range | 0.03–8 | <0.015 to >8 |
| GM MIC | 0.39 | 0.22 | |
| MIC50 | 0.5 | 0.125 | |
| MIC90 | 2 | 8 |
Abbreviation: VVC, vulvovaginal candidiasis.
Result of antifungal drugs sensitivity test of different 25S rDNA genotypes
| Antifungal agents | MIC | Genotype A | Genotype B | Genotype C |
|---|---|---|---|---|
| Amphotericin B | MIC range (ug/ml) | 0.125–1 | 0.25–1 | 0.125–1 |
| GM MIC (ug/ml) | 0.70 | 0.76 | 0.70 | |
| MIC50 | 1 | 1 | 1 | |
| MIC90 | 1 | 1 | 1 | |
| 5‐Fluorocytosine | MIC range (ug/ml) | <0.125 to >64 | <0.125–1 | <0.125–0.5 |
| GM MIC (ug/ml) | 1.22 | 0.17 | 0.17 | |
| MIC50 | 2 | 0.125 | 0.125 | |
| MIC90 | 4 | 0.5 | 0.5 | |
| Fluconazole | MIC range (ug/ml) | 0.06 to >64 | 0.125 to >64 | 0.25 to >64 |
| GM MIC (ug/ml) | 1.25 | 1.06 | 2.00 | |
| MIC50 | 1 | 0.5 | 2 | |
| MIC90 | 8 | 16 | 64 | |
| Itraconazole | MIC range (ug/ml) | <0.015 to >8 | 0.03 to >8 | 0.03 to >8 |
| GM MIC (ug/ml) | 0.30 | 0.21 | 0.50 | |
| MIC50 | 0.25 | 0.125 | 0.25 | |
| MIC90 | 2 | 8 | 8 |
Mortality of mice infected with strains
| Group | Strain | CAI genotype | Source | Mice | Mortality10 days | Mortality21 days | Mortality5 months |
|---|---|---|---|---|---|---|---|
| 1 | GYF006 | 30–45 | VVC | 12 | 2 (16.6%) | 6 (50.0%) | 11 (91.6%) |
| 2 | GYZ249 | 21–21 | Lung cancer | 12 | 5 (41.6%) | 9 (75.0%) | 9 (75.0%) |
| 3 | ATCC 10231 | Untested | Bronchopneumonia | 12 | 3 (25.0%) | 7 (58.3%) | 9 (75.0%) |
| 4 | GYWu27 | 21–21 | HIV/AIDS | 12 | 3 (25.0%) | 7 (58.3%) | 12 (100.0%) |
| 5 | GYWu45 | 21–21 | HIV/AIDS | 12 | 2 (16.6%) | 8 (66.7%) | 12 (100.0%) |
| 6 | GYF76 | 32–46 | VVC | 12 | 1 (8.3%) | 6 (50.0%) | 11 (91.6%) |
| 7 | GYWu20 | 21–33 | HIV/AIDS | 12 | 3 (25%) | 7 (58.3%) | 12 (100.0%) |
| 8 | GYF091 | 30–46 | VVC | 12 | 2 (16.6%) | 6 (50.0%) | 12 (100.0%) |
| 9 | GYZ210 | 21–33 | Lung cancer | 12 | 4 (33.3%) | 8 (66.7%) | 11 (91.6%) |
| 10 | GYZ072 | 21–33 | Lung cancer | 12 | 5 (41.6%) | 6 (50.0%) | 11 (91.6%) |
| 11 | BK60 | Untested | Normal | 12 | 2 (16.6%) | 5 (41.6%) | 8 (66.7%) |
| 12 | S165 | Untested | Normal | 12 | 2 (16.6%) | 6 (50.0%) | 10 (83.3%) |
| 13 | 1107 | Untested | Normal | 12 | 1 (8.3%) | 4 (33.3%) | 8 (66.7%) |
| 14 | Saline | ‐ | ‐ | 12 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Abbreviation: VVC, vulvovaginal candidiasis.
Figure 2Survival curves of KM mice following infection with strains. Mice were inoculated i.v. with 5 × 105 cells of strains from lung cancer, HIV/AIDS, VVC, and normal (asymptomatic) individuals; conditions of mice were assessed daily for 21 days [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 3Pathological changes in the kidney of the mice infected with (HE staining, A × 400, B × 200, C × 400, D × 200). (a) Kidney section of mouse (died on Day 48) inoculated by GYW045 of genotype 21–21; (b) kidney section of mouse (died on Day 67) inoculated by GYZ210 of genotype 21–33; (c) kidney sections of mouse (euthanized on Day 168) inoculated by GYZ249 of genotype 21–21; (d) kidney section of normal mouse (scale bar = 50 μm) [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 4Immunostained samples for Ki‐67 labelling index in the kidney of the mice infected with . (a) Ki‐67 labelling index of mouse died within 30 days (3%); (b) Ki‐67 labelling index of mouse died after 30 days (40%; scale bar = 50 μm) [Colour figure can be viewed at wileyonlinelibrary.com]